CYT-0851 Plus Capecitabine Demonstrates Efficacy in Advanced Ovarian Cancer

The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.

Related Keywords

Markus Renschler ,International Conference On Molecular ,Molecular Targets ,News ,Ovarian Cancer ,Gynecologic Oncology ,Xeloda ,Capecitabine ,Cyt 0851 ,Nct03997968 ,